Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Complete remission following targeted therapy in BRAF V600E: mutant pulmonary lymphangitic carcinomatosis secondary to rectal cancer-a case report.

Journal of medical case reports·2026

Same author

Real-World Outcomes of Mantle Cell Lymphoma Treated With Rituximab-Based Chemotherapy Regimens: Experience From a Single Institution in Vietnam.

Cancer control : journal of the Moffitt Cancer Center·2026

Same author

Co-infection of cytomegalovirus and Epstein-Barr virus-induced pneumonitis following hepatitis B reactivation in an esophageal cancer patient: A case report.

Medicine·2026

Same author

Optimizing afatinib dosage: enhancing treatment outcomes and minimizing toxicities in advanced EGFR-mutated non-small cell lung cancer patients in Vietnam.

Therapeutic advances in medical oncology·2025

Same author

Therapeutic Outcomes of Osimertinib in EGFR - Mutant Non-Small Cell Lung Cancer With Brain Metastases: Results From a Retrospective Study at Vietnam National Cancer Hospital.

Cancer control : journal of the Moffitt Cancer Center·2025

Same author

Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam.

Therapeutic advances in respiratory disease·2025

Same journal

Patterns of Body Composition Changes and Their Predictors During Cancer Therapy in Newly Diagnosed Adult Oncology Patients With Varying Baseline Nutritional Status at a Tertiary Hospital in Ethiopia: A Prospective Cohort Study.

Cancer reports (Hoboken, N.J.)·2026

Same journal

Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design.

Cancer reports (Hoboken, N.J.)·2026

Same journal

Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B-ALL After CAR-T Therapy and HSCT: A Case Series.

Cancer reports (Hoboken, N.J.)·2026

Same journal

Development of a Tumor-Bearing Animal Model to Evaluate Chemotherapy Efficacy and Toxicity.

Cancer reports (Hoboken, N.J.)·2026

Same journal

CCT7 Expression Affects the Prognosis of Lung Adenocarcinoma.

Cancer reports (Hoboken, N.J.)·2026

Same journal

Pembrolizumab-Induced Myositis: Diagnostic and Therapeutic Challenges From Two Case Reports and a Narrative Review.

Cancer reports (Hoboken, N.J.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 10, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Case Report: A Bilateral Synchronous Primary Non-Small Cell Lung Cancer Patient With Two Different EGFR Mutations.

Thanh-Dung Quach^1,2, Kien Hung Do³, Dinh Tung Nguyen^1,2

¹Oncology Center, Vinmec Times City International Hospital, Vinmec Healthcare System, Hanoi, Vietnam.

Cancer Reports (Hoboken, N.J.)

|August 26, 2025

Summary

This summary is machine-generated.

This case study details a rare instance of synchronous bilateral non-small cell lung cancer (NSCLC) with two distinct epidermal growth factor receptor (EGFR) mutations. Comprehensive molecular profiling is crucial for effective NSCLC treatment strategies.

Keywords:

EGFR mutation afatinib non‐small cell lung cancer

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

Related Experiment Videos

Last Updated: Sep 10, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
Epidermal growth factor receptor (EGFR) mutations are key drivers in NSCLC, particularly in Asian populations.
Typically, NSCLC patients present with a single EGFR mutation; multiple mutations are exceedingly rare.

Observation:

A 70-year-old Vietnamese woman, a non-smoker, was diagnosed with synchronous bilateral primary NSCLC.
The right lung lesion had an EGFR G719C mutation (exon 18), while the left lung lesion had an EGFR exon 19 deletion.
The patient received surgical resection for the left lung and afatinib for the right lung.

Findings:

The patient experienced tumor reduction and disease stability for one year following treatment.
Disease progression occurred after one year, indicating the need for ongoing monitoring and adaptive treatment strategies.
This case highlights the challenge of managing bilateral NSCLC with differing genetic profiles.

Implications:

Synchronous bilateral NSCLC with distinct EGFR mutations presents unique diagnostic and management complexities.
Comprehensive molecular profiling is essential for tailoring treatment strategies in such rare cases.
Personalized medicine approaches are vital for improving outcomes in patients with complex NSCLC genetic profiles.